Table of Contents Author Guidelines Submit a Manuscript
Journal of Obesity
Volume 2010, Article ID 602537, 5 pages
Clinical Study

Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients

1Group of Obesity & Metabolic Syndrome, Endocrinology Service, Hospital das Clínicas, Faculty of Medicine, University of Sao Paulo, 05410-000 São Paulo, Brazil
2Department of Nutrition and Dietitian, Clínica Alfredo Halpern, 05410-000 São Paulo, Brazil

Received 24 June 2009; Revised 17 November 2009; Accepted 3 December 2009

Academic Editor: Renato Pasquali

Copyright © 2010 Alfredo Halpern et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To assess the efficacy and tolerability of the association sibutramine (10–20 mg/day) and orlistat (120 mg 2-3 times a day) in the treatment of obesity in a six-month open trial. Methods. 446 overweight and obese patients who sought treatment for obesity in a private clinic were assessed every 2 weeks during a period of 3 and 6 months. Results. After 3 months, the mean weight loss was 10.5 kg ( 9.8% of the initial weight, 𝑛 = 2 6 3 ), and after 6 months, the mean weight loss was 13.9 kg ( 12.8% of the initial weight, 𝑛 = 9 7 ). The tolerability of such association was quite acceptable and coherent with the action mechanism of each component. Conclusions. The association of orlistat and sibutramine is quite efficient and it seems to promote a higher rate of weight loss than that reported in clinical studies performed with each drug separately.